Key facts
- It has raised $350K; the latest was Early Stage VC ($350K) in Aug 2025.
- Notable investors include GVFL, AIC-LMCP Foundation, TiE Global.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for QRL Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for QRL Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About QRL Bioscience
Operator of a biotechnology company intended to develop personalized cell-based therapies for chronic degenerative diseases. The company offers an autologous advanced biologics platform that uses live-cell-based regenerative therapies, enabling customers to benefit from targeted, personalized treatments that accelerate healing, reduce hospitalization and improve long-term health outcomes.
- Sector
- Healthcare
- HQ
- Gandhinagar, India
- Founded
- 2023
- Employees
- 6
- Website
- qrlbioscience.com/
- Ownership
- Privately Held (backing)
QRL Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in QRL Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on QRL Bioscience in its N-PORT filings yet. We sweep new filings monthly.